The Visionary Future of CAR T-Cell Therapy
Noopur Raje, MD, Marcela Maus, MD, PhD and Matthew Frigault, MD discuss the power and evolution of immune therapies, specifically, CAR T-Cell therapy in treating cancer.
Departments, Centers, & Programs:
Treats:
Mass General Cancer Center
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2023-2024.
Noopur Raje, MD, Marcela Maus, MD, PhD and Matthew Frigault, MD discuss the power and evolution of immune therapies, specifically, CAR T-Cell therapy in treating cancer.
Billy Costa talks with Dr. Matt Frigault and oncology social worker Lauren DeMarco to learn more about the latest in CAR T-cell therapies and what it all means for patients.
It’s fitting that the investigators who developed a new CAR T-based treatment for glioblastoma called their treatment platform “CAR-TEAM” cells, as it took a true team effort to bring their concept from the lab to the clinic.
A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment.
In this interview with Targeted Oncology, Matthew Frigault, MD discusses follow-up data on the efficacy and safety of CART-ddBCMA for the treatment of patients with relapsed/refractory multiple myeloma, particularly in later-line settings.